Mylan's Generic Version of Prilosec Approved by FDA

Chrissie Cole
Contributor
Visit Chrissie Cole on FacebookVisit Chrissie Cole on Twitter
Posted by Chrissie ColeJanuary 23, 2009 11:18 AM
Tags: None

A generic formulation of Prilosec, from Mylan, has been approved by the U.S. Food and Drug Administration (FDA) for immediate launch.

Prilosec, marketed by AstraZeneca, is used for the treatment of gastric ulcers and gastro-esophageal reflux disease.

Acid reflux or "heartburn" occurs when acid escapes from the stomach and moves up and into the esophagus. The esophagus is not designed to withstand stomach acid.

The new approval is for 40-mg delayed-release capsules. Previously approved versions of Impax's generic Prilosec, including 10 and 20-mg capsules are one of 12 products included in an alliance which first launched in 2001 with a subsidiary of Teva Pharmaceuticals Industries Ltd.

0 Comments

Have an opinion about this post? Please consider leaving a comment or subscribing to the feed to have future articles delivered to your feed reader.

Comments for this article are closed.

Subscribe to InjuryBoard New York City

InjuryBoard New York City RSS Feeds

Keep up with the latest updates using your favorite RSS reader

Injury Board New York City is brought to you by Napoli Bern Ripka, LLP

Legal Assistance Center

More Info
Napoli Bern Ripka, LLP 866-735-1102 Ext. 300 www.nbrlawfirm.com
google
Personal Injury Lawyers Serving: New York City, Manhattan, Bronx, Brooklyn, Long Island, Nassau, Queens, Staten Island, Suffolk, Yonkers
350 5th AvenueSuite 7413, New York, New York 10118 [ Show Map ]
Better Business Bureau Accredited Business Confidential

Your question will be referred to an attorney near you. If your question is of a legal nature, then by submitting this form you agree you are not forming a formal attorney / client relationship. Read our full privacy policy.

Looking for an InjuryBoard attorney closer to home? Click here.

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address